secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001193125-25-069668
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio announces board changes: two directors depart, two new directors elected
--------------------------------------------------------------------------------

- Simon Tate resigned as director on March 27, 2025, also leaving audit and nominating committees; no disagreement.
- Adam Rosenberg will not seek re-election at 2025 annual meeting; no disagreement with company.
- Board expanded from 7 to 8; Alexander (Bo) Cumbo and Kimberlee Drapkin elected effective March 28, 2025.
- Cumbo to chair compensation committee; Drapkin to chair audit committee.
- Each new director received option to purchase 80,000 shares at $1.28/share, vesting over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525069668/0001193125-25-069668-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312525069668/d853219d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-069668

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer